Two-phase releasing immune-stimulating composite orchestrates protection against microbial infections

“…In this investigation, a porous ALN hydrogel was developed as a drug reservoir and residence for DCs mature. Crosslinked with calcium ions and gelatinized quickly via local administration, ALN is a kind of natural polysaccharide widely used in tissue engineering and drug-controlled release 55 , 56 . This injectable pore-forming hydrogel, composed of a bulk and porous network, involves simple preparation, minimally invasive delivery, biodegradable properties, tunable release kinetics through modulation of molecular weight and concentration, as well as ready incorporation of a wide array of therapeutics 57 .…”

Section: Discussionmentioning

confidence: 99%

An injectable signal-amplifying device elicits a specific immune response against malignant glioblastoma

Qiu,

Chen,

et al. 2023

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

“…When activated, TLRs recruit a group of adaptors, including myeloid differentiation factor 88 (MyD88), Toll-interleukin receptor (TIR) domain containing adaptor protein (TIRAP), TIR-domain-containing adaptor inducing interferon-β (TRIF), and TRIF-related adaptor molecule (TRAM), and then activate downstream signal transduction, thereby simultaneously activating the corresponding transcription factors, consequently leading to the secretion of chemokines and cytokines [ 32 ]. In the same way, adjuvants that target NLRs, such as muramyl dipeptide [ 33 ], and adjuvants that target RLRs, such as M8 [ 34 ], also activate the innate immune response and produce an immune-enhancing effect.…”

Section: Mechanism Of Vaccine Adjuvantsmentioning

confidence: 99%

Self-adjuvanting cancer nanovaccines

Liao

Huang

et al. 2022

J Nanobiotechnol

View full text Add to dashboard Cite

Nanovaccines, a new generation of vaccines that use nanoparticles as carriers and/or adjuvants, have been widely used in the prevention and treatment of various diseases, including cancer. Nanovaccines have sparked considerable interest in cancer therapy due to a variety of advantages, including improved access to lymph nodes (LN), optimal packing and presentation of antigens, and induction of a persistent anti-tumor immune response. As a delivery system for cancer vaccines, various types of nanoparticles have been designed to facilitate the delivery of antigens and adjuvants to lymphoid organs and antigen-presenting cells (APCs). Particularly, some types of nanoparticles are able to confer an immune-enhancing capability and can themselves be utilized for adjuvant-like effect for vaccines, suggesting a direction for a better use of nanomaterials and the optimization of cancer vaccines. However, this role of nanoparticles in vaccines has not been well studied. To further elucidate the role of self-adjuvanting nanovaccines in cancer therapy, we review the mechanisms of antitumor vaccine adjuvants with respect to nanovaccines with self-adjuvanting properties, including enhancing cross-presentation, targeting signaling pathways, biomimicking of the natural invasion process of pathogens, and further unknown mechanisms. We surveyed self-adjuvanting cancer nanovaccines in clinical research and discussed their advantages and challenges. In this review, we classified self-adjuvanting cancer nanovaccines according to the underlying immunomodulatory mechanism, which may provide mechanistic insights into the design of nanovaccines in the future. Graphical Abstract

show abstract

Two-phase releasing immune-stimulating composite orchestrates protection against microbial infections

Cited by 13 publications

References 32 publications

An injectable all-small-molecule dynamic metallogel for suppressing sepsis

An injectable all-small-molecule dynamic metallogel for suppressing sepsis

An injectable signal-amplifying device elicits a specific immune response against malignant glioblastoma

Self-adjuvanting cancer nanovaccines

Contact Info

Product

Resources

About